1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial

Authors :: U. Scheuring
Matthew D. Hellmann
L. Poole
Solange Peters
Christopher Abbosh
M. Kuziora
A. Dey
Yashaswi Shrestha
Rajiv Raja
Zhongwu Lai
J.C. Barrett
Naiyer A. Rizvi
Source :: Annals of Oncology. 32:S989-S990
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Chemotherapy
business.industry
medicine.medical_treatment
Hematology
Immunotherapy
chemistry.chemical_compound
chemistry
Internal medicine
medicine
In patient
business
DNA

Full Text Access

Tools